Teva: We Believe In Biosimilars, But Pipeline And Timing Come First
‘There’ll Be Bumpiness But Opportunity Is Massive,’ Says New CEO Francis
Teva’s newly appointed CEO Richard Francis has underlined the company’s commitment to biosimilars, buoyed by his experience overseeing their progress at his former employer Sandoz.
You may also be interested in...
Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.
Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.
Alvotech has been bolstered by a US FDA confirmation that its AVT02 adalimumab candidate can be approved as an interchangeable biosimilar based on the data provided in its filing – but first, the Icelandic firm must pass an upcoming facility inspection.